Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25% import duty on Indian goods. Investors were also monitoring the ongoing earnings season. The Nifty settled below the 24,600 level after hitting the days high of 24,784.15 in mid-morning trade.

Barring the Nifty FMCG index, all the other sectoral indices on the NSE ended in red.

As per provisional closing data, the barometer index, the S&P BSE Sensex declined 585.67 points or 0.72% to 80,599.91. The Nifty 50 index lost 203 points or 0.82% to 24,565.35.

The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index slipped 1.37% and the S&P BSE Small-Cap index declined 1.59%.

The market breadth was weak. On the BSE, 1,307 shares rose and 2,711 shares fell. A total of 151 shares were unchanged.

The NSE’s India VIX, a gauge of the market’s expectation of volatility over the near term, rallied 3.74% to 11.98

Related Posts

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer. The closing date for the buyback…

Boehringer Ingelheim launches AI centre for pharma research in London

Bengaluru: German drugmaker Boehringer Ingelheim is launching a ​centre for artificial ​intelligence and machine learning in London, it said ​on Monday, as it seeks to expand its AI capabilities in…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid